Results 101 to 110 of about 766,818 (299)

PD-1: Dual guard for immunopathology

Oncotarget, 2015
Despite remarkable medical development, chronic infectious diseases caused by the infections with persistent pathogens such as hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), and mycobacterium tuberculosis (M.tb), have not been conquered yet.
Hye Ryun, Kim, Hyo Jin, Park, Sang-Jun, Ha   +2 more
openaire   +3 more sources

Striking enhancement at the site of radiation for nivolumab-induced Stevens-Johnson syndrome [PDF]

, 2018
Stevens-Johnson syndrome is a rare adverse cutaneous drug reaction characterized by epidermal detachment of
Al-Omari, Ahmed, Rancour, Elizabeth A., Shah, Kishan M.   +2 more
core  

Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA

Molecular Oncology, EarlyView.
Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson, Anders Lade Nielsen, Boe Sandahl Sorensen   +2 more
wiley   +1 more source

PD-1 is conserved from sharks to humans: new insights into PD-1, PD-L1, PD-L2, and SHP-2 evolution

Frontiers in Immunology
Programmed cell death protein 1 (PD-1) is an immune checkpoint molecule until recently believed to exist only in tetrapod species. However, together with a very recent study dedicated to the CD28/CTLA4 molecule family, this study—using database ...
Ryohei Kondo, Kohei Kondo, Kei Nabeshima, Akihiko Nishikimi, Yasumasa Ishida, Toshiaki Shigeoka, Johannes M. Dijkstra   +6 more
doaj   +1 more source

Combination Therapies of Guadecitabine and Immune Checkpoint Inhibitors in a Murine Triple-Negative Breast Cancer Model [PDF]

, 2020
Combination Therapies of Guadecitabine and Immune Checkpoint Inhibitors in a Murine Triple-Negative Breast Cancer Model Jamie-Jean Gilmer, Depts. of Biology and Chemistry, with Dr. Sarah Golding, Dept.
Gilmer, Jamie-Jean
core   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Increased PD-1 expression in livers associated with PD-1-antibody-induced hepatotoxicity

BMC Immunology
Abstract Vanishing bile duct syndrome (VBDS) is a serious drug induced liver injury characterized by chronic cholestasis and loss of intrahepatic bile ducts. VBDS has been reported also following checkpoint inhibitor treatment. We compared CD3 + , CD4 + , CD8 + , CD20 + , CD57 + , PD-1 + and PD-L1 + lymphocyte infiltrates in liver biopsies of
Saarela, Miro, Parviainen, Essi, Lleo, Ana, di Tommaso, Luca, Raunio, Hanna, Kankaanranta, Krista, Vuopala, Katri, Rönkä, Aino, Nurmenniemi, Sini, Kallio, Raija, Jukkola, Arja, Selander, Katri S.   +11 more
openaire   +4 more sources

Interpretation of some Yb-based valence-fluctuating crystals as approximants to a dodecagonal quasicrystal

, 2018
The hexagonal ZrNiAl-type (space group: P-62m) and the tetragonal Mo2FeB2-type (space group: P4/mbm) structures, which are frequently formed in the same Yb-based alloys and exhibit physical properties related to valence-fluctuation, can be regarded as ...
de Boissieu, Marc, Deguchi, Kazuhiko, Ishimasa, Tsutomu, Mihalkovič, Marek, Sato, Noriaki K.   +4 more
core   +2 more sources

In vitro models of cancer‐associated fibroblast heterogeneity uncover subtype‐specific effects of CRISPR perturbations

Molecular Oncology, EarlyView.
Development of therapies targeting cancer‐associated fibroblasts (CAFs) necessitates preclinical model systems that faithfully represent CAF–tumor biology. We established an in vitro coculture system of patient‐derived pancreatic CAFs and tumor cell lines and demonstrated its recapitulation of primary CAF–tumor biology with single‐cell transcriptomics ...
Elysia Saputra, Shamsudheen Karuthedath Vellarikkal, Lixia Li, Hong Sun, Khoa Nguyen, Amber Montano, Suchitra Natarajan, Federica Piccioni, Alex Michael Tamburino, Xin Yu, Aleksandra Katarzyna Olow   +10 more
wiley   +1 more source

PD-1/PD-L1 Inhibitors in Cervical Cancer

Frontiers in Pharmacology, 2019
Cervical cancer is one of the most common gynecological tumors, and the majority of early-stage cervical cancer patients achieve good recovery through surgical treatment and concurrent chemoradiotherapy (CCRT).
Yuncong Liu, Yuncong Liu, Li Wu, Ruizhan Tong, Feiyue Yang, Limei Yin, Limei Yin, Mengqian Li, Mengqian Li, Liting You, Liting You, Jianxin Xue, Jianxin Xue, You Lu, You Lu   +14 more
doaj   +1 more source